Neuroprotective properties of a standardized extract from Myracrodruon urundeuva Fr. All. (Aroeira-Do-Sertão), as evaluated by a Parkinson's disease model in rats

Parkinson's Disease

Volumn 2014, Issue , 2014, Pages

  Calou, Iana ^a   Bandeira, Mary Anne ^a   Aguiar Galvão, Wellida ^a   Cerqueira, Gilberto ^a   Siqueira, Rafaelly ^a   Neves, Kelly Rose ^a   Brito, Gerly Anne ^a   Viana, Glauce ^a,b  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b Laboratory of Pharmacology and Physiology   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOMORPHINE; MYRACRODRUON URUNDEUVA EXTRACT; NEUROPROTECTIVE AGENT; PLANT EXTRACT; POLYPHENOL; TANNIN DERIVATIVE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BARK; BUD; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EXPERIMENTAL BEHAVIORAL TEST; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MALE; NEUROCHEMISTRY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; RAT; ROTAROD TEST; SHOOT; STEREOTAXIC SURGERY;

EID: 84904113605     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1155/2014/519615     Document Type: Article

References (46)

1. Rodrigues L. V., Ferreira F. V., Regadas F. S. P., Matos D., de Barros Viana G. S., Morphologic and morphometric analyses of acetic acid-induced colitis in rats after treatment with enemas from Myracrodruon urundeuva Fr. All. (Aroeira do Sertão). Phytotherapy Research 2002 16 3 267 272 2-s2.0-0035990641 10.1002/ptr.841 (Pubitemid 34534956)
2. Souza S. M. C., Aquino L. C. M., Milach A. C. Jr., Bandeira M. A. M., Nobre M. E. P., Viana G. S. B., Antiinflammatory and antiulcer properties of tannins from Myracrodruon urundeuva Allemão (Anacardiaceae) in rodents. Phytotherapy Research 2007 21 3 220 225 2-s2.0-33947599586 10.1002/ptr.2011 (Pubitemid 46479670)
3. Schofield P., Mbugua D. M., Pell A. N., Analysis of condensed tannins: a review. Animal Feed Science and Technology 2001 91 1-2 21 40 2-s2.0-0035897523 10.1016/S0377-8401(01)00228-0 (Pubitemid 32515977)
4. Viana G. S. B., Bandeira M. A. M., Matos F. J. A., Analgesic and antiinflammatory effects of chalcones isolated from Myracrodruon urundeuva Allemão. Phytomedicine 2003 10 2-3 189 195 2-s2.0-0037358112 10.1078/094471103321659924 (Pubitemid 36433216)
5. Hassanpour S., Maherisis N., Eshratkhah B., Baghbani Mehmandar F., Plants and secondary metabolites (tannins): a review. International Journal of Forest, Soil and Erosion 2011 1 1
6. Gupta V. K., Sharma S. K., Plants as natural antioxidants. Natural Product Radiance 2006 5 326 334
7. Bravo L., Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutrition Reviews 1998 56 11 317 333 2-s2.0-0031721802 (Pubitemid 28532456)
8. Parr A. J., Bolwell G. P., Phenols in the plant and in mam. The potential for possible nutritional enhancement of the diet by modifying the phenols content or profile. Journal of the Science of Food and Agriculture 2000 80 985 1012 (Pubitemid 30319394)
9. King A., Young G., Characteristics and occurrence of phenolic phytochemicals. Journal of the American Dietetic Association 1999 99 2 213 218 2-s2.0-0032984234 10.1016/S0002-8223(99)00051-6 (Pubitemid 29077349)
10. Bandeira M. A. M., Viana G. S. B., Galvão W. R. A., Braz-Filho R., Matos F. J. A.,. (In memoriam). Miracrodruon urundeuva Fr. All. (aroeira-do-sertão). In: Viana GSB, Leal LKAM, Vasconcelos SMM (orgs.) Plantas Medicinais da Caatinga: Atividades Biológicas e Potencial Terapêutico. Fortaleza: Universidade Federal do Ceará/ Expressão Gráfica Editora Ltda., 2013
11. Simola N., Morelli M., Carta A. R., The 6-hydroxydopamine model of Parkinson's disease. Neurotoxicity Research 2007 11 3-4 151 167 2-s2.0-34548458484 10.1007/BF03033565
12. Metz G. A., Tse A., Ballermann M., Smith L. K., Fouad K., The unilateral 6-OHDA rat model of Parkinson's disease revisited: An electromyographic and behavioural analysis. European Journal of Neuroscience 2005 22 3 735 744 2-s2.0-23944434938 10.1111/j.1460-9568.2005.04238.x (Pubitemid 41192283)
13. Blandini F., Armentero M.-T., Martignoni E., The 6-hydroxydopamine model: news from the past. Parkinsonism and Related Disorders 2008 14 supplement 2 S124 S129 2-s2.0-47049116273 10.1016/j.parkreldis.2008.04.015
14. Paxinos G., Watson C., The Rat Brain in Stereotaxic Coordinates 1998 New York, NY, USA Academic Press
15. Mandel R. J., Effect of acute L-dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease. Experimental Neurology 2000 161 1 212 219 2-s2.0-0034010260 10.1006/exnr.1999.7245 (Pubitemid 30136543)
16. Kim M. J., Lee Y. H., Kwak J., Na Y., Yoon H. G., Protective effects of a chalcone derivative against A β -induced oxidative stress and neuronal damage. BMB Reports 2011 44 11 730 734 2-s2.0-84863230324 10.5483/BMBRep.2011. 44.11.730
17. Rosland J. H., Hunskaar S., Hole K., Diazepam attenuates morphine antinociception test-dependently in mice. Pharmacology and Toxicology 1990 66 5 382 386 2-s2.0-0025175424 (Pubitemid 20330501)
18. Khan M. S., Tabrez S., Priyadarshini M., Priyamvada S., Khan M. M., Targeting Parkinson's-tyrosine hydroxylase and oxidative stress as points of interventions. CNS and Neurological Disorders-Drug Targets 2012 11 4 369 380 2-s2.0-84862588042
19. Zhu Y., Zhang J., Zeng Y., Overview of tyrosine Hydroxylase in Parkinson's disease. CNS and Neurological Disorders-Drug Targets 2012 11 4 350 358 2-s2.0-84862581664
20. Wu D. C., Tieu K., Cohen O., Choi D. K., Vila M., Jackson-Lewis V., Teismann P., Przedborski S., Glial cell response: a pathogenic factor in Parkinson's disease. Journal of NeuroVirology 2002 8 6 551 558 2-s2.0-0036962803 10.1080/13550280290100905 (Pubitemid 36109117)
21. Sekiyama K., Sugama S., Fujita M., Sekigawa A., Takamatsu Y., Waragai M., Takenouchi T., Hashimoto M., Neuroinflammation in Parkinson's disease and related disorders: a lesson from genetically manipulated mouse models of α -synucleinopathies. Parkinson's Disease 2012 2012 8 2-s2.0-84859761962 10.1155/2012/271732 271732
22. Batovska D. I., Todorova I. T., Trends in utilization of the pharmacological potential of chalcones. Current Clinical Pharmacology 2010 5 1 1 29 2-s2.0-77950854525 10.2174/157488410790410579
23. Rahman M. A., Chalcone: a valuable insight into the recent advances and potential pharmacological activities. Chemical Sciences Journal 2011
24. Sahu N. K., Balbhadra S. S., Choudhary J., Kohli D. V., Exploring pharmacological significance of chalcone scaffold: a review. Current Medicinal Chemistry 2012 19 2 209 225 2-s2.0-84857587699
25. Nobre-Júnior H. V., Oliveira R. A., Maia F. D., Nogueira M. A. S., de Moraes M. O., Bandeira M. A. M., Andrade G. M., Viana G. S. B., Neuroprotective effects of chalcones from Myracrodruon urundeuva on 6-hydroxydopamine-induced cytotoxicity in rat mesencephalic cells. Neurochemical Research 2009 34 6 1066 1075 2-s2.0-64249161436 10.1007/s11064-008-9876-5
26. Luthman J., Fredriksson A., Lewander T., Jonsson G., Archer T., Effects of d-amphetamine and methylphenidate on hyperactivity produced by neonatal 6-hydroxydopamine treatment. Psychopharmacology 1989 99 4 550 557 2-s2.0-0024445048 (Pubitemid 19273114)
27. González-Hernández T., Barroso-Chinea P., de la Cruz Muros I., del Mar Pérez-Delgado M., Rodríguez M., Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons. Journal of Comparative Neurology 2004 479 2 198 215 2-s2.0-4744366999 10.1002/cne.20323 (Pubitemid 39314891)
28. Rodriguez-Pallares J., Parga J. A., Muñoz A., Rey P., Guerra M. J., Labandeira-Garcia J. L., Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. Journal of Neurochemistry 2007 103 1 145 156 2-s2.0-34548620779 10.1111/j.1471-4159.2007.04699.x (Pubitemid 47404195)
29. Sachs C., Jonsson G., Effects of 6 hydroxydopamine on central noradrenaline neurons during ontogeny. Brain Research 1975 99 2 277 291 2-s2.0-0016766160 10.1016/0006-8993(75)90029-3
30. Kumar R., Agarwal A. K., Seth P. K., Free radical-generated neurotoxicity of 6-hydroxydopamine. Journal of Neurochemistry 1995 64 4 1703 1707 2-s2.0-0028916715
31. Soto-Otero R., Méndez-Álvarez E., Hermida-Ameijeiras Á., Muñoz-Patiño A. M., Labandeira-Garcia J. L., Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. Journal of Neurochemistry 2000 74 4 1605 1612 2-s2.0-0342369569 10.1046/j.1471-4159.2000.0741605.x (Pubitemid 30163982)
32. Glinka Y., Tipton K. F., Youdim M. B. H., Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine. Journal of Neurochemistry 1996 66 5 2004 2010 2-s2.0-0029969350
33. Glinka Y., Gassen M., Youdim M. B. H., Mechanism of 6-hydroxydopamine neurotoxicity. Journal of Neural Transmission 1997 Supplement 50 55 66 2-s2.0-0030614642 (Pubitemid 27055928)
34. Iancu R., Mohapel P., Brundin P., Paul G., Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behavioural Brain Research 2005 162 1 1 10 2-s2.0-19444370500 10.1016/j.bbr.2005.02.023 (Pubitemid 40726275)
35. Van Keuren K. R., Stodgell C. J., Schroeder S. R., Tessel R. E., Fixed-ratio discrimination training as replacement therapy in Parkinson's disease: studies in a 6-hydroxydopamine-treated rat model. Brain Research 1998 780 1 56 66 2-s2.0-0032484516 10.1016/S0006-8993(97)01184-0 (Pubitemid 28068079)
36. Sossi V., de la Fuente-Fernández R., Holden J. E., Doudet D. J., McKenzie J., Stoessl A. J., Ruth T. J., Increase in dopamine turnover occurs early in Parkinson's disease: Evidence from a new modeling approach to PET 18F-fluorodopa data. Journal of Cerebral Blood Flow and Metabolism 2002 22 2 232 239 2-s2.0-0036167679 (Pubitemid 34135654)
37. Sossi V., de la Fuente-Fernández R., Holden J. E., Schulzer M., Ruth T. J., Stoessl J., Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms. Journal of Cerebral Blood Flow and Metabolism 2004 24 8 869 876 2-s2.0-3843057052 (Pubitemid 39045404)
38. Feve A. P., Current status of tyrosine hydroxylase in management of Parkinson's disease. CNS and Neurological Disorders-Drug Targets 2012 11 4 450 455 2-s2.0-84862581390
39. Haavik J., Toska K., Tyrosine hydroxylase and Parkinson's disease. Molecular Neurobiology 1998 16 3 285 309 2-s2.0-0031808220 (Pubitemid 28268547)
40. McGeer P. L., Itagaki S., Tago H., McGeer E. G., Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neuroscience Letters 1987 79 1-2 195 200 2-s2.0-0023633015 (Pubitemid 17144469)
41. McGeer P. L., Itagaki S., Boyes B. E., McGeer E. G., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988 38 8 1285 1291 2-s2.0-0023789193
42. Cagnin A., Brooks D. J., Kennedy A. M., Gunn R. N., Myers R., Turkheimer F. E., Jones T., Banati R. B., In-vivo measurement of activated microglia in dementia. The Lancet 2001 358 9280 461 467 2-s2.0-0035845283 10.1016/S0140-6736(01)05625-2 (Pubitemid 32769854)
43. Cicchetti F., Brownell A. L., Williams K., Chen Y. I., Livni E., Isacson O., Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. European Journal of Neuroscience 2002 15 6 991 998 2-s2.0-0036459335 10.1046/j.1460-9568.2002.01938.x (Pubitemid 35463634)
44. Wilms H., Zecca L., Rosenstiel P., Sievers J., Deuschl G., Lucius R., Inflammation in Parkinson's diseases and other neurodegenerative diseases: Cause and therapeutic implications. Current Pharmaceutical Design 2007 13 18 1925 1928 2-s2.0-34347357758 10.2174/138161207780858429 (Pubitemid 47017994)
45. Rodrigues R. W. P., Gomide V. C., Chadi G., Astroglial and microglial activation in the Wistar rat ventral tegmental area after a single striatal injection of 6-hydroxydopamine. International Journal of Neuroscience 2004 114 2 197 216 2-s2.0-0842312949 10.1080/00207450490249338 (Pubitemid 38173518)
46. Silva C., Fuxe K., Chadi G., Involvement of astroglial fibroblast growth factor-2 and microglia in the nigral 6-OHDA Parkinsonism and a possible role of glucocorticoid hormone on the glial mediated local trophism and wound repair. Journal of Neural Transmission 2009 supplement 73 185 202 2-s2.0-77952312016 10.1007/978-3-211-92660-4-15